Home / Insider News / OTLK
Insider Buy Cluster Buy CEO Buy New Position April 19, 2021

KENYON LAWRENCE A purchased ~$55K in Outlook Therapeutics, Inc. stock

Outlook Therapeutics, Inc. (OTLK)  ·  CEO, Pres, CFO, Treas & Secy  ·  Data via SEC EDGAR Form 4

Verity Signals Research Published Updated

= insider buy date

90-day return

+28.4%

vs SPY +2.7%

OTLK price after insider trade by KENYON LAWRENCE A

Insider

KENYON LAWRENCE A

Role

CEO, Pres, CFO, Treas & Secy

Transaction

Open-Market Purchase

Approx. Value

~$55K

Trade Date

Apr 19, 2021

Company

Outlook Therapeutics, Inc.

Ticker

OTLK

Source

SEC EDGAR Form 4

Strong conviction signal

Scored above average across multiple factors. Roughly 15% of insider trades qualify as Strong.

~$55K purchase

A personal investment by a corporate insider. Even smaller trades can be meaningful when combined with other factors like timing and role.

CEO, Pres, CFO, Treas & Secy

CEOs have the deepest knowledge of company operations. Academic research shows CEO purchases outperform other insider trades by a wide margin.

3 insiders traded in the same window

When multiple insiders independently buy within 30 days, it's called a cluster. Studies show clustered insider purchases outperform solo trades significantly, because several people with inside knowledge are reaching the same conclusion.

+28.4% in 90 days (S&P 500: +2.7%)

This trade beat the S&P 500 by 25.7 percentage points over 90 days. We track performance on every insider trade so you can see who consistently outperforms.

KL

How good is KENYON LAWRENCE A at picking stocks?

Full track record: win rate, average return, and performance vs S&P 500

See track record
3

KENYON LAWRENCE A wasn't the only one buying.

3 insiders at Outlook Therapeutics, Inc. traded within the same 30-day window.

See who else bought · Free

On April 19, 2021, KENYON LAWRENCE A — CEO, Pres, CFO, Treas & Secy of Outlook Therapeutics, Inc. — filed a Form 4 with the SEC disclosing an open-market purchase of approximately ~$55K in Outlook Therapeutics, Inc. (OTLK) stock.

This transaction was part of a cluster — 3 insiders at Outlook Therapeutics, Inc. made open-market purchases within the same 30-day window. Cluster activity from multiple independent insiders is one of the most studied patterns in insider trading research.

Under Section 16(a) of the Securities Exchange Act of 1934, corporate insiders must report all open-market stock transactions to the SEC within two business days. These filings — known as Form 4s — are publicly available on the SEC's EDGAR database. VeritySignals filters and scores the full Form 4 stream to surface high-conviction signals like this one.

In the 90 days following this trade, OTLK returned +28.4% versus +2.7% for the S&P 500 over the same period.

Full Conviction Analysis

Sign up free to see signal strength details, or upgrade for the full 15-factor breakdown.

Upgrade to Trader

Get notified the next time KENYON LAWRENCE A trades

Free alerts · No credit card · Instant notification

Set free alert

All data sourced from publicly available SEC Form 4 filings via EDGAR · Not financial advice · Past performance does not guarantee future results.

Signal strength Strong
Trade size ~$55K
Insider role CEO, Pres, CFO, Treas & Secy
Cluster 3 insiders
90-day return +28.4%
vs S&P 500 +25.7%

What is this?

When company executives buy or sell their own stock, they must report it to the SEC within 2 days. These public filings reveal what the people who know the company best are doing with their own money.

Why does it matter?

Insiders can sell for many reasons (taxes, diversification, expenses), but they generally only buy for one: they think the stock is going up. That's why insider purchases are more predictive than sales.

What makes a trade "strong"?

We score trades on 15+ factors: the insider's role (CEO > director), trade size relative to their salary, whether other insiders also bought (clusters), and historical accuracy of the insider.

Read our full methodology →

Never miss a signal

Get notified when high-conviction insiders buy. Free account, no credit card.

Sign up free